ArticleBlood cancer journal2018
Effect of the BTK inhibitor ibrutinib on macrophage- and γδ T cell-mediated response against Mycobacterium tuberculosis.
Abstract readLetter
In one paragraph
Article in Blood cancer journal, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed, 1 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Macrophage-associated kinase signaling in atherosclerosis - a systematic review.Cell communication and signaling : CCS · 2026Pooled it
- Frontline acalabrutinib, lenalidomide and rituximab for advanced stage follicular lymphoma with high tumor burden: phase II trial.Nature communications · 2025Trial
- A randomized, placebo-controlled trial of the BTK inhibitor zanubrutinib in hospitalized patients with COVID-19 respiratory distress: immune biomarker and clinical findings.Frontiers in immunology · 2024Trial
- Safety and Efficacy of Pembrolizumab in Combination with Acalabrutinib in Advanced Head and Neck Squamous Cell Carcinoma: Phase 2 Proof-of-Concept Study.Clinical cancer research : an official journal of the American Association for Cancer Research · 2022Trial
- Acalabrutinib in combination with rituximab and lenalidomide in patients with relapsed or refractory follicular lymphoma: Results of the phase 1b open-label study (ACE-LY-003).British journal of haematology · 2025Article
- The contribution of BTK signaling in myeloid cells to neuroinflammation.Frontiers in immunology · 2025Article
- Review
- BTK inhibitor-induced defects in human neutrophil effector activity against Aspergillus fumigatus are restored by TNF-α.JCI insight · 2024Article
- BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies.Journal of hematology & oncology · 2022Review
- Review
- Review
- Ibrutinib protects T cells in patients with CLL from proliferation-induced senescence.Journal of translational medicine · 2021Article
- Article
- Bruton's tyrosine kinase: an emerging targeted therapy in myeloid cells within the tumor microenvironment.Cancer immunology, immunotherapy : CII · 2021Review
- Targeting Bruton tyrosine kinase using non-covalent inhibitors in B cell malignancies.Journal of hematology & oncology · 2021Review
- BTK Promotes Atherosclerosis by Regulating Oxidative Stress, Mitochondrial Injury, and ER Stress of Macrophages.Oxidative medicine and cellular longevity · 2021Article
- Article
- Relative and Quantitative Phosphoproteome Analysis of Macrophages in Response to Infection by Virulent and AvirulentJournal of proteome research · 2020Article
- Effects of BTK signalling in pathogenic microorganism infections.Journal of cellular and molecular medicine · 2019Review
- Lysine-Specific Histone Demethylase 1A Regulates Macrophage Polarization and Checkpoint Molecules in the Tumor Microenvironment of Triple-Negative Breast Cancer.Frontiers in immunology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors.
Ana ColadoLaboratorio de Inmunología Oncológica, Instituto de Medicina Experimental (IMEX)-CONICET-Academia Nacional de Medicina (ANM), CABA, Argentina.
Melanie GenoulaLaboratorio de Inmunología de Enfermedades Respiratorias, IMEX-CONICET-ANM, CABA, Argentina.
Céline CougouleInternational Associated Laboratory (LIA) CNRS/CONICET "IM-TB/HIV" (1167), Toulouse, France.
José L Marín FrancoLaboratorio de Inmunología de Enfermedades Respiratorias, IMEX-CONICET-ANM, CABA, Argentina.
María B AlmejúnLaboratorio de Inmunología Oncológica, Instituto de Medicina Experimental (IMEX)-CONICET-Academia Nacional de Medicina (ANM), CABA, Argentina.
Denise RisnikLaboratorio de Inmunología Oncológica, Instituto de Medicina Experimental (IMEX)-CONICET-Academia Nacional de Medicina (ANM), CABA, Argentina.
Denise KviatcovskyLaboratorio de Inmunología de Enfermedades Respiratorias, IMEX-CONICET-ANM, CABA, Argentina.
Enrique PodazaLaboratorio de Inmunología Oncológica, Instituto de Medicina Experimental (IMEX)-CONICET-Academia Nacional de Medicina (ANM), CABA, Argentina.
Esteban E ElíasLaboratorio de Inmunología Oncológica, Instituto de Medicina Experimental (IMEX)-CONICET-Academia Nacional de Medicina (ANM), CABA, Argentina.
Federico FuentesIMEX-CONICET-ANM, CABA, Argentina.
Isabelle Maridonneau-PariniInternational Associated Laboratory (LIA) CNRS/CONICET "IM-TB/HIV" (1167), Toulouse, France.
Fernando R BezaresSección de Hematología, Hospital General de Agudos Dr. Teodoro Álvarez, CABA, Argentina.
Horacio Fernandez GreccoDepartamento de Hematología, Sanatorio Julio Méndez, CABA, Argentina.
María CabrejoDepartamento de Hematología, Sanatorio Julio Méndez, CABA, Argentina.
Carolina JancicLaboratorio de Inmunidad Innata, MEX-CONICET-ANM, CABA, Argentina.
María Del Carmen SasiainLaboratorio de Inmunología de Enfermedades Respiratorias, IMEX-CONICET-ANM, CABA, Argentina.
Mirta GiordanoLaboratorio de Inmunología Oncológica, Instituto de Medicina Experimental (IMEX)-CONICET-Academia Nacional de Medicina (ANM), CABA, Argentina.
Romina GamberaleLaboratorio de Inmunología Oncológica, Instituto de Medicina Experimental (IMEX)-CONICET-Academia Nacional de Medicina (ANM), CABA, Argentina.
Luciana BalboaLaboratorio de Inmunología de Enfermedades Respiratorias, IMEX-CONICET-ANM, CABA, Argentina.
Mercedes BorgeLaboratorio de Inmunología Oncológica, Instituto de Medicina Experimental (IMEX)-CONICET-Academia Nacional de Medicina (ANM), CABA, Argentina. mercedesborge@hotmail.com.ORCID http://orcid.org/0000-0002-1256-2364
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
AdenineAgammaglobulinaemia Tyrosine KinaseHumansMacrophagesMycobacterium tuberculosisPiperidinesProtein-Tyrosine KinasesPyrazolesPyrimidinesReceptors, Antigen, T-Cell, gamma-deltaT-LymphocytesAdenineAgammaglobulinaemia Tyrosine KinaseBTK protein, humanibrutinibPiperidinesProtein-Tyrosine KinasesPyrazolesPyrimidinesReceptors, Antigen, T-Cell, gamma-delta
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.